首页> 美国卫生研究院文献>Journal of the Endocrine Society >OR23-05 Human Absorption Metabolism Excretion and Absolute Oral Bioavailability of 14C-CRN00808 an Orally Bioavailable Nonpeptide Selective Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
【2h】

OR23-05 Human Absorption Metabolism Excretion and Absolute Oral Bioavailability of 14C-CRN00808 an Orally Bioavailable Nonpeptide Selective Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly

机译:14C-CRN00808口服生物可利用非肽选择性生长抑素受体2(SST2)偏离激动剂的人类吸收新陈代谢排泄和绝对口服生物利用度用于治疗烦恼性肠道

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Injected depot formulations of somatostatin peptide analogs are routinely used to treat acromegaly and neuroendocrine tumors (NETs). {"type":"entrez-protein","attrs":{"text":"CRN00808","term_id":"1048626668","term_text":"CRN00808"}}CRN00808, a small molecule nonpeptide selective somatostatin receptor 2 (sst2) agonist, is being evaluated for efficacy and safety in patients with acromegaly. The current Phase 1 study was conducted in two Parts: In Part A, the absorption, metabolism, excretion, and mass balance of a single oral dose of 20 mg [14C]-{"type":"entrez-protein","attrs":{"text":"CRN00808","term_id":"1048626668","term_text":"CRN00808"}}CRN00808 (3.0 MBq) oral solution was characterized in six healthy male subjects. Plasma, blood, urine, and feces were collected for up to 432 hours, and were analyzed for total radioactivity and {"type":"entrez-protein","attrs":{"text":"CRN00808","term_id":"1048626668","term_text":"CRN00808"}}CRN00808 concentrations (plasma only). Metabolite profiling was conducted on the plasma, urine, and feces samples. In Part B, the absolute bioavailability of {"type":"entrez-protein","attrs":{"text":"CRN00808","term_id":"1048626668","term_text":"CRN00808"}}CRN00808 was determined by administering a single oral dose of 20 mg {"type":"entrez-protein","attrs":{"text":"CRN00808","term_id":"1048626668","term_text":"CRN00808"}}CRN00808 compared with a single micro-tracer intravenous (IV) bolus injection of 50 µg [14C]-{"type":"entrez-protein","attrs":{"text":"CRN00808","term_id":"1048626668","term_text":"CRN00808"}}CRN00808 (0.0185 MBq) in five healthy male subjects. The IV dose was administered approximately 90 minutes after the oral dose. Plasma samples were collected for up to 144 hours and were analyzed for total radioactivity and {"type":"entrez-protein","attrs":{"text":"CRN00808","term_id":"1048626668","term_text":"CRN00808"}}CRN00808 concentrations (plasma only).
机译:促生长素抑制素肽类似物的注射储库制剂通常用于治疗肢端肥大症和神经内分泌肿瘤(母语)。 { “类型”: “的Entrez蛋白”, “ATTRS”:{ “文本”: “CRN00808”, “term_id”: “1048626668”, “term_text”: “CRN00808”}} CRN00808,小分子非肽选择性促生长素抑制素受体2(sst 2的)激动剂,正被评估疗效和安全性在肢端肥大症患者。当前阶段1研究是分两部分进行:在A部分中,吸收,代谢,排泄,和20毫克的[14 C]单次口服剂量的质量平衡 - {“类型”:“的Entrez蛋白”,“ATTRS “:{” 文本 “:” CRN00808" , “term_id”: “1048626668”, “term_text”: “CRN00808”}} CRN00808(3.0活度)口服溶液,其特征在于在六名健康男性受试者。血浆,血液,尿液和粪便收集长达432小时,并进行了分析总放射性和{“类型”:“Entrez的蛋白质”,“ATTRS”:{“文”:“CRN00808”,“term_id” : “1048626668”, “term_text”: “CRN00808”}} CRN00808浓度(血浆只)。代谢物谱被在血浆,尿和粪便样品进行。在B部分中,绝对生物利用度{ “类型”: “的Entrez蛋白”, “ATTRS”:{ “文本”: “CRN00808”, “term_id”: “1048626668”, “term_text”: “CRN00808”}} CRN00808 “的Entrez蛋白”, “ATTRS”:{ “文本”: “CRN00808”, “term_id”: “1048626668”, “term_text”: “CRN00808” 被通过施用20毫克{ “类型” 单次口服剂量确定}} CRN00808用50μg[14 C]的单个微示踪剂静脉内(IV)推注相比 - { “类型”: “的Entrez蛋白”, “ATTRS”:{ “文本”: “CRN00808”, “term_id” : “1048626668”, “term_text”:在五个健康男性受试者 “CRN00808”}} CRN00808(0.0185活度)。的IV剂量口服给药后约90分钟施用。收集血浆样品用于多达144个小时,并进行了分析总放射性和{“类型”:“的Entrez蛋白”,“ATTRS”:{“文本”:“CRN00808”,“term_id”:“1048626668”,“term_text “:” CRN00808" }} CRN00808浓度(血浆只)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号